Zevra Therapeutics, Inc. (ZVRA) Misses Q1 EPS by $2.25

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported Q1 EPS of ($0.06), $2.25 worse than the analyst estimate of $2.19. Revenue for the quarter came in at $25.9 million versus the consensus estimate of $22.49 million.

For earnings history and earnings-related data on Zevra Therapeutics, Inc. (ZVRA) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• Stifel Starts Tower Semiconductor (TSEM) at Buy, Top Pick
• Palo Alto Networks (PANW) Tops Q4 EPS by 4c, Offers Guidance